This is a single arm, open label and non-randomized clinical study with 5 to 10 patients will be enrolled.
The primary objective of this study is to evaluate the safety of Neo-T in the treatment of advanced solid tumors.~The secondary objective of this study is to evaluate preliminarily the effect of Neo-T in the treatment of advanced solid tumors.